Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Prospective PhaseⅡ Study of Reduced Toxicity Conditioning Consisted of High Dose-Cytarabine, Fludarabine, Cyclophosphamide +/- Total Body Irradiation Followed By Allogeneic Stem Cell Transplantation

Senji Kasahara, MD PhD, Hiroshi Nakamura, MD, Yuto Kaneda, MD, Yoshikazu Ikoma, MD, Eri Takada, MD, Kimihiro Yamaguchi, MD, Yuhei Shibata, MD PhD, Takuro Matsumoto, MDPhD, Nobuhiko Nakamura, MD PhD, Soranobu Ninomiya, MD PhD, Junichi Kitagawa, MD PhD, Hideko Goto, MD PhD, Takeshi Hara, MD PhD, Michio Sawada, MD PhD, Takeshi Takahashi, MD PhD, Masahito Shimizu, MD PhD, Hisashi Tsurumi, MD

Blood (2017) 130 (Supplement 1): 1960.

https://doi.org/10.1182/blood.V130.Suppl_1.1960.1960

Published: 2017

Journal Articles

Monitoring of Adult T-Cell Leukemia-Lymphoma Cells in Patients Receiving Mogamulizumab, a Humanized Anti-CCR4 Monoclonal Antibody, Using T-Cell Receptor Repertoire Analysis

Masato Saito, Takashi Ishida, MD PhD, Itaru Urakawa, PhD, Toshihiko Ishii, Asahi Ito, MD PhD, Ayako Masaki, MD PhD, Susumu Suzuki, PhD, Shigeru Kusumoto, MD PhD, Hirokazu Komatsu, MD PhD, Hiroshi Inagaki, MD PhD, Takeshi Takahashi, PhD, Ryuzo Ueda, MD PhD, Shinsuke Iida, MD PhD

Blood (2016) 128 (22): 1744.

https://doi.org/10.1182/blood.V128.22.1744.1744

Published: 2016

Journal Articles

First Preclinical Report of the Efficacy and PD Results of KHK2823, a Non-Fucosylated Fully Human Monoclonal Antibody Against IL-3Rα

Tadakazu Akiyama, PhD, Shin-ichiro Takayanagi, PhD, Yoshimi Maekawa, Kohta Miyawaki, MD, Fumiaki Jinnouchi, MD, Takashi Jiromaru, MD, Takeshi Sugio, MD, Shinya Daitoku, MD, Hirotake Kusumoto, MD, Munetake Shimabe, PhD, Satoshi Nishikawa, Kengo Yamawaki, Kousuke Iijima, Masanori Hiura, Takeshi Takahashi, PhD, Yoshikane Kikushige, MD PhD, Hiromi Iwasaki, MD PhD, Koichi Akashi, MD PhD, Tomonori Tawara, PhD

Blood (2015) 126 (23): 1349.

https://doi.org/10.1182/blood.V126.23.1349.1349

Published: 2015

Journal Articles

Management of Adverse Events Associated with Dasatinib during Early Periods of Therapy in the Treatment of Chronic Myeloid Leukemia -a Clinical Report of Daria-01 Study

Shuichi Mizuta, MD, Hisashi Tsurumi, Masashi Sawa, MD PhD, Kana Matsumoto, PhD, Kotaro Miyao, MD, Takeshi Hara, MD PhD, Takeshi Takahashi, MD PhD, Reona Sakemura, MD, Akio Kohno, MD PhD, Mari Oba, Satoshi Morita, PhD, Junichi Sakamoto, MDPhD, Nobuhiko Emi, MDPhD

Blood (2014) 124 (21): 4537.

https://doi.org/10.1182/blood.V124.21.4537.4537

Published: 2014

Journal Articles

A Randomized Phase II/III Study of R-THP-Cop Vs R-CHOP for Patients Younger Than 70 Years with DLBCL

Naoe Goto, MD PhD, Takuro Matsumoto, MD, Yuhei Shibata, MD, Junichi Kitagawa, MD PhD, Nobuhiro Kanemura, MD PhD, Yoshikawa Takeshi, MDPhD, Senji Kasahara, MD PhD, Hideko Goto, MDPhD, Kenji Fukuno, MD, Takeshi Hara, MD PhD, Toshiki Yamada, MD PhD, Michio Sawada, MD PhD, Takeshi Takahashi, MDPhD, Koshiro Saito, MD PhD, Hisataka Moriwaki, Prof., Hisashi Tsurumi, MD PhD

Blood (2014) 124 (21): 3078.

https://doi.org/10.1182/blood.V124.21.3078.3078

Published: 2014

Journal Articles

High Response Rate and Acceptable Toxicity of R-P-Imvp-16/CBDCA for Relapsed or Refractory Aggressive B-Cell Lymphoma

Takuro Matsumoto, MD, Nobuhiko Nakamura, MD PhD, Yuhei Shibata, MD, Hiroshi Nakamura, MD, Ryoko Mabuchi, MD, Junichi Kitagawa, MD PhD, Nobuhiro Kanemura, MD PhD, Naoe Goto, MD PhD, Senji Kasahara, MD PhD, Hideko Goto, MD PhD, Kenji Fukuno, MD PhD, Takeshi Hara, MD PhD, Toshiki Yamada, MD PhD, Michio Sawada, MD PhD, Takeshi Takahashi, MD PhD, Masami Oyama, MD PhD, Koshiro Saito, MD PhD, Hisashi Tsurumi, MD PhD

Blood (2014) 124 (21): 4418.

https://doi.org/10.1182/blood.V124.21.4418.4418

Published: 2014

Journal Articles

Serum IL-10 and IL-8 Among Variable Cytokines Derived From Helper T Cells Might Be Associated with Prognoses for Malignant Lymphoma Patients

Junichi Kitagawa, MD, PhD, Hisashi Tsurumi, MD, PhD, Naoe Goto, MD, PhD, Katsuyoshi Takata, MD, PhD, Nobuhiko Nakamura, MD, Nobuhiro Kanemura, MD, PhD, Takeshi Hara, MD, PhD, Senji Kasahara, MD, PhD, Takeshi Takahashi, MD, PhD, Tadashi Yoshino, Prof., Hisataka Moriwaki, Prof.

Blood (2012) 120 (21): 5107.

https://doi.org/10.1182/blood.V120.21.5107.5107

Published: 2012

Journal Articles

A Humanized Anti-Ganglioside GM2 Antibody, BIW-8962, Exhibits ADCC/CDC Activity against Multiple Myeloma Cells and Potent Anti- Tumor Activity in Mouse Xenograft Models.

Toshihiko Ishii, Asher Alban Chanan-Khan, MD, Jazur Jafferjee, MD, Noreen Ersing, Takeshi Takahashi, PhD, Masato Mizutani, PhD, Yukimasa Shiotsu, PhD, Nobuo Hanai, PhD

Blood (2008) 112 (11): 1718.

https://doi.org/10.1182/blood.V112.11.1718.1718

Published: 2008

Journal Articles

A Phase II Study of the Combination Chemotherapy Consisted of Rituximab and THP-COP Regimen as First-Line Treatment for Patients with Diffuse Large B-Cell Lymphoma

Hisashi Tsurumi, MD, PhD, Naoe Goto, Takeshi Hara, Senji Kasahara, Nobuhiro Kanemura, Junichi Kitagawa, MD, Takeshi Yoshikawa, Toshiki Yamada, Michio Sawada, Takeshi Takahashi, Tsuyoshi Takami, Hisataka Moriwaki

Blood (2008) 112 (11): 3599.

https://doi.org/10.1182/blood.V112.11.3599.3599

Published: 2008

Journal Articles

Serum Interleukin-18 Levels Are Associated with Response to Treatment and Survival in Patients with Aggressive Non-Hodgkin’s Lymphoma.

Naoe Goto, MD, Hisashi Tsurumi, MD, PhD, Masao Takemura, PhD, Takeshi Hara, MD, PhD, Michio Sawada, MD, PhD, Toshiki Yamada, MD, PhD, Senji Kasahara, MD, PhD, Nobuhiro Kanemura, MD, Takeshi Takahashi, MD, PhD, Mitsuru Seishima, MD, PhD, Tsuyoshi Takami, MD, PhD, Koshiro Saito, MD, PhD, Hisataka Moriwaki, MD, PhD

Blood (2004) 104 (11): 4543.

https://doi.org/10.1182/blood.V104.11.4543.4543

Published: 2004

Journal Articles

Fas or Fas Ligand Expression Can Determine the Clinical Outcome of Germinal Center Type in Diffuse Large B Cell Lymphoma.

Yasushi Kojima, MD, Hisashi Tsurumi, MD, PhD, Naoe Goto, MD, Michio Sawada, MD, PhD, Toshiki Yamada, MD, PhD, Takeshi Hara, MD, PhD, Takeshi Takahashi, MD, PhD, Tetsuya Yamada, MD, PhD, Masanao Saio, MD, PhD, Eiichi Tomita, MD, PhD, Tsuyoshi Takami, MD, PhD, Hisataka Moriwaki, MD, PhD

Blood (2004) 104 (11): 3267.

https://doi.org/10.1182/blood.V104.11.3267.3267

Published: 2004

Journal Articles

Serum-Soluble Tumor Necrosis Factor Receptor 2 (sTNF-R2) Level Determines Clinical Outcome in Patients with Aggressive Non-Hodgkin’s Lymphoma.

Hisashi Tsurumi, MD, PhD, Naoe Goto, MD, Masao Takemura, PhD, Takeshi Hara, MD, PhD, Michio Sawada, MD, PhD, Toshiki Yamada, MD, PhD, Senji Kasahara, MD, PhD, Nobuhiro Kanemura, MD, Takeshi Takahashi, MD, PhD, Masami Oyama, MD, PhD, Eiichi Tomita, MD, PhD, Tsuyoshi Takami, MD, PhD, Hisataka Moriwaki, MD, PhD

Blood (2004) 104 (11): 3271.

https://doi.org/10.1182/blood.V104.11.3271.3271

Published: 2004

NARROW

Prospective PhaseⅡ Study of Reduced Toxicity Conditioning Consisted of High Dose-Cytarabine, Fludarabine, Cyclophosphamide +/- Total Body Irradiation Followed By Allogeneic Stem Cell Transplantation

Monitoring of Adult T-Cell Leukemia-Lymphoma Cells in Patients Receiving Mogamulizumab, a Humanized Anti-CCR4 Monoclonal Antibody, Using T-Cell Receptor Repertoire Analysis

First Preclinical Report of the Efficacy and PD Results of KHK2823, a Non-Fucosylated Fully Human Monoclonal Antibody Against IL-3Rα

Management of Adverse Events Associated with Dasatinib during Early Periods of Therapy in the Treatment of Chronic Myeloid Leukemia -a Clinical Report of Daria-01 Study

A Randomized Phase II/III Study of R-THP-Cop Vs R-CHOP for Patients Younger Than 70 Years with DLBCL

High Response Rate and Acceptable Toxicity of R-P-Imvp-16/CBDCA for Relapsed or Refractory Aggressive B-Cell Lymphoma

Serum IL-10 and IL-8 Among Variable Cytokines Derived From Helper T Cells Might Be Associated with Prognoses for Malignant Lymphoma Patients

A Humanized Anti-Ganglioside GM2 Antibody, BIW-8962, Exhibits ADCC/CDC Activity against Multiple Myeloma Cells and Potent Anti- Tumor Activity in Mouse Xenograft Models.

A Phase II Study of the Combination Chemotherapy Consisted of Rituximab and THP-COP Regimen as First-Line Treatment for Patients with Diffuse Large B-Cell Lymphoma

Serum Interleukin-18 Levels Are Associated with Response to Treatment and Survival in Patients with Aggressive Non-Hodgkin’s Lymphoma.

Fas or Fas Ligand Expression Can Determine the Clinical Outcome of Germinal Center Type in Diffuse Large B Cell Lymphoma.

Serum-Soluble Tumor Necrosis Factor Receptor 2 (sTNF-R2) Level Determines Clinical Outcome in Patients with Aggressive Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only